Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
184036-34-8Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2PHWXUGHIIBDVKD-UHFFFAOYSA-NSitaxentan is a member of benzodioxoles.
Pharmaceuticals
Pharmaceuticals -> Listed in ZINC15
Pharmaceuticals -> Antihypertensives
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Sitaxsentan
vMost-DILI-concern
8
Withdrawn
DOI:10.1016/j.drudis.2016.02.015
C - Cardiovascular system
QC - Cardiovascular system
Sitaxentan belongs to a class of drugs known as endothelin receptor antagonists (ERAs). Patients with PAH have elevated levels of endothelin, a potent blood vessel constrictor, in their plasma and lung tissue. Sitaxentan blocks the binding of endothelin to its receptors, thereby negating endothelin's deleterious effects.
Sitaxentan is a competitive antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors. Under normal conditions, endothelin-1 binding of ET-A or ET-B receptors causes pulmonary vasoconstriction. By blocking this interaction, Sitaxentan decreases pulmonary vascular resistance. Sitaxentan has a higher affinity for ET-A than ET-B.
70-100%
Renal (50 to 60%) Fecal (40 to 50%)
184036-34-8、210421-64-0DTXSID0057673CHEMBL282724CHEBI:135736